You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameQuinapril
Accession NumberDB00881  (APRD00523)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Quinapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to quinaprilat (quinapril diacid) following oral administration. Quinaprilat is a competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Quinapril may be used to treat essential hypertension and congestive heart failure.

Structure
Thumb
Synonyms
Quinapril
Quinaprilum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accupriltablet, film coated5 mg/1oralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
Accupriltablet, film coated20 mg/1oralCardinal Health1991-11-19Not applicableUs
Accupriltablet, film coated10 mg/1oralCardinal Health1991-11-19Not applicableUs
Accupriltablet, film coated40 mg/1oralbryant ranch prepack1991-11-19Not applicableUs
Accupriltablet, film coated40 mg/1oralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
Accupriltablet, film coated20 mg/1oralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
Accupriltablet, film coated10 mg/1oralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
Accupril 5mg Tabtablet5 mgoralPfizer Canada Inc1992-12-31Not applicableCanada
Accupril Tab 10mgtablet10 mgoralPfizer Canada Inc1992-12-31Not applicableCanada
Accupril Tab 20mgtablet20 mgoralPfizer Canada Inc1992-12-31Not applicableCanada
Accupril Tab 40mgtablet40 mgoralPfizer Canada Inc1992-12-31Not applicableCanada
Gd-quinapriltablet20 mgoralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
Gd-quinapriltablet10 mgoralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
Gd-quinapriltablet5 mgoralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
Gd-quinapriltablet40 mgoralGenmed A Division Of Pfizer Canada Inc2014-06-02Not applicableCanada
PMS-quinapriltablet40 mgoralPharmascience Inc2013-11-18Not applicableCanada
PMS-quinapriltablet20 mgoralPharmascience Inc2013-11-18Not applicableCanada
PMS-quinapriltablet10 mgoralPharmascience Inc2013-11-18Not applicableCanada
PMS-quinapriltablet5 mgoralPharmascience Inc2013-11-18Not applicableCanada
Quinapriltablet10 mgoralPro Doc Limitee2013-11-28Not applicableCanada
Quinapriltablet40 mgoralPro Doc Limitee2013-11-28Not applicableCanada
Quinapriltablet5 mgoralPro Doc Limitee2013-11-28Not applicableCanada
Quinapriltablet20 mgoralPro Doc Limitee2013-11-28Not applicableCanada
Quinapril Hydrochloridetablet, film coated10 mg/1oralCarilion Materials Management1991-11-19Not applicableUs
Quinapril Hydrochloridetablet, film coated5 mg/1oralCarilion Materials Management1991-11-19Not applicableUs
Quinapril Hydrochloridetablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.1991-11-19Not applicableUs
Quinapril Hydrochloridetablet, film coated40 mg/1oralGreenstone LLC1991-11-19Not applicableUs
Quinapril Hydrochloridetablet, film coated20 mg/1oralGreenstone LLC1991-11-19Not applicableUs
Quinapril Hydrochloridetablet, film coated10 mg/1oralGreenstone LLC1991-11-19Not applicableUs
Quinapril Hydrochloridetablet, film coated20 mg/1oralCarilion Materials Management1991-11-19Not applicableUs
Quinapril Hydrochloridetablet, film coated5 mg/1oralGreenstone LLC1991-11-19Not applicableUs
Ran-quinapriltablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-quinapriltablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-quinapriltablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-quinapriltablet5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-quinapriltablet10 mgoralApotex Inc2013-07-02Not applicableCanada
Apo-quinapriltablet5 mgoralApotex Inc2013-07-02Not applicableCanada
Apo-quinapriltablet40 mgoralApotex Inc2013-07-02Not applicableCanada
Apo-quinapriltablet20 mgoralApotex Inc2013-07-02Not applicableCanada
Quinapriltablet20 mg/1oralAv Pak2014-08-052016-03-11Us
Quinapriltablet40 mg/1oralBlue Point Laboratories2014-07-18Not applicableUs
Quinapriltablet10 mg/1oralProficient Rx LP2012-01-20Not applicableUs
Quinapriltablet, film coated20 mg/1oralPhysicians Total Care, Inc.2005-03-03Not applicableUs
Quinapriltablet5 mg/1oralRebel Distributors Corp2010-02-26Not applicableUs
Quinapriltablet, film coated10 mg/1oralRanbaxy Pharmaceuticals Inc.2007-09-24Not applicableUs
Quinapriltablet40 mg/1oralLupin Pharmaceuticals, Inc.2014-08-01Not applicableUs
Quinapriltablet20 mg/1oralDr.Reddy's Laboratories Limited2007-07-20Not applicableUs
Quinapriltablet40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-02-26Not applicableUs
Quinapriltablet, film coated10 mg/1oralAurobindo Pharma Limited2013-04-29Not applicableUs
Quinapriltablet5 mg/1oralBlue Point Laboratories2014-02-25Not applicableUs
Quinapriltablet, film coated40 mg/1oralSun Pharmaceutical Industries Limited2009-06-18Not applicableUs
Quinapriltablet10 mg/1oralAv Pak2014-08-052016-03-11Us
Quinapriltablet, film coated5 mg/1oralAurobindo Pharma Limited2013-04-29Not applicableUs
Quinapriltablet10 mg/1oralDr.Reddy's Laboratories Limited2007-07-20Not applicableUs
Quinapriltablet40 mg/1oralCamber Pharmaceuticals, Inc.2012-01-20Not applicableUs
Quinapriltablet10 mg/1oralBlue Point Laboratories2014-02-25Not applicableUs
Quinapriltablet, film coated20 mg/1oralSun Pharmaceutical Industries Limited2009-06-18Not applicableUs
Quinapriltablet5 mg/1oralAv Pak2014-08-052016-03-11Us
Quinapriltablet, film coated40 mg/1oralbryant ranch prepack2010-02-25Not applicableUs
Quinapriltablet40 mg/1oralLupin Pharmaceuticals, Inc.2007-02-26Not applicableUs
Quinapriltablet5 mg/1oralDr.Reddy's Laboratories Limited2007-07-20Not applicableUs
Quinapriltablet20 mg/1oralCamber Pharmaceuticals, Inc.2012-01-20Not applicableUs
Quinapriltablet, film coated10 mg/1oralSun Pharmaceutical Industries Limited2009-06-18Not applicableUs
Quinapriltablet40 mg/1oralAv Kare, Inc.2012-08-022016-01-21Us
Quinapriltablet20 mg/1oralBlue Point Laboratories2014-02-25Not applicableUs
Quinapriltablet, film coated20 mg/1oralbryant ranch prepack2010-02-25Not applicableUs
Quinapriltablet20 mg/1oralLupin Pharmaceuticals, Inc.2007-02-26Not applicableUs
Quinapriltablet, film coated5 mg/1oralPhysicians Total Care, Inc.2005-07-22Not applicableUs
Quinapriltablet10 mg/1oralCamber Pharmaceuticals, Inc.2012-01-20Not applicableUs
Quinapriltablet, film coated5 mg/1oralSun Pharmaceutical Industries Limited2009-06-18Not applicableUs
Quinapriltablet20 mg/1oralAv Kare, Inc.2012-08-022016-01-21Us
Quinapriltablet40 mg/1oralBlue Point Laboratories2014-02-25Not applicableUs
Quinapriltablet, film coated40 mg/1oralPhysicians Total Care, Inc.2007-11-28Not applicableUs
Quinapriltablet5 mg/1oralCamber Pharmaceuticals, Inc.2012-01-20Not applicableUs
Quinapriltablet, film coated40 mg/1oralRanbaxy Pharmaceuticals Inc.2007-09-24Not applicableUs
Quinapriltablet10 mg/1oralLupin Pharmaceuticals, Inc.2007-02-26Not applicableUs
Quinapriltablet40 mg/1oralCardinal Health2012-01-20Not applicableUs
Quinapriltablet10 mg/1oralAv Kare, Inc.2012-08-022016-01-21Us
Quinapriltablet, film coated40 mg/1oralAurobindo Pharma Limited2013-04-29Not applicableUs
Quinapriltablet, film coated5 mg/1oralRanbaxy Pharmaceuticals Inc.2007-09-24Not applicableUs
Quinapriltablet40 mg/1oralAv Pak2014-08-052016-03-11Us
Quinapriltablet20 mg/1oralAmerican Health Packaging2015-09-15Not applicableUs
Quinapriltablet, film coated10 mg/1oralPhysicians Total Care, Inc.2005-03-07Not applicableUs
Quinapriltablet10 mg/1oralRebel Distributors Corp2010-02-26Not applicableUs
Quinapriltablet, film coated20 mg/1oralRanbaxy Pharmaceuticals Inc.2007-09-24Not applicableUs
Quinapriltablet5 mg/1oralLupin Pharmaceuticals, Inc.2007-02-26Not applicableUs
Quinapriltablet40 mg/1oralDr.Reddy's Laboratories Limited2007-07-20Not applicableUs
Quinapriltablet5 mg/1oralAv Kare, Inc.2012-08-022016-01-21Us
Quinapriltablet, film coated20 mg/1oralAurobindo Pharma Limited2013-04-29Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AccuprinPfizer (Italy)
AccuproPfizer (Austria, Denmark, Finland, Germany, Hungary, Ireland, Sweden, Switzerland, United Kingdom, Ukraine), Godecke (Czech Republic, Germany, Poland, Russia), Parke, Davis (Germany)
AcequinNot Available
AcuitelNot Available
KorecNot Available
QuinazilNot Available
Brand mixtures
NameLabellerIngredients
AccureticParke Davis Div Of Pfizer Inc
Accuretic 10/12.5 mgPfizer Canada Inc
Accuretic 20/12.5 mgPfizer Canada Inc
Accuretic 20/25 mgPfizer Canada Inc
Apo-quinapril/hctzApotex Inc
Gd-quinapril HctzGenmed A Division Of Pfizer Canada Inc
Quinapril HCl and HydrochlorothiazideGavis Pharmaceuticals, LLC.
Quinapril Hydrochloride and HydrochlorothiazideMylan Pharmaceuticals Inc.
Quinapril Hydrochloride/hydrochlorothiazideLake Erie Medical DBA Quality Care Products LLC
Salts
Name/CASStructureProperties
Quinapril Hydrochloride
82586-55-8
Thumb
  • InChI Key: IBBLRJGOOANPTQ-JKVLGAQCSA-N
  • Monoisotopic Mass: 474.192149819
  • Average Mass: 474.977
DBSALT000465
Categories
UNIIRJ84Y44811
CAS number85441-61-8
WeightAverage: 438.5161
Monoisotopic: 438.21547208
Chemical FormulaC25H30N2O5
InChI KeyInChIKey=JSDRRTOADPPCHY-HSQYWUDLSA-N
InChI
InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1
IUPAC Name
(3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[[email protected]]1C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • Alpha-amino acid ester
  • Alpha-amino acid amide
  • Tetrahydroisoquinoline
  • Phenylpropylamine
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Aralkylamine
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of hypertension and as adjunct therapy in the treatment of congestive heart failure. May also be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
PharmacodynamicsQuinapril is a nonpeptide, non-sulfhydryl prodrug that is deesterified to quinaprilat (quinapril diacid), its major active metabolite following oral administration. Quinaprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of quinaprilat by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Quinaprilat, the principle active metabolite of quinapril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Quinaprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
Related Articles
AbsorptionPeak plasma concentrations of quinapril occur within one hour following oral administration. The extent of absorption is at least 60%. The rate and extent of quinapril absorption are diminished moderately (approximately 25-30%) when ACCUPRIL tablets are administered during a high-fat meal.
Volume of distributionNot Available
Protein binding97%
Metabolism

Hepatic.

SubstrateEnzymesProduct
Quinapril
Not Available
QuinaprilatDetails
Route of eliminationQuinaprilat is eliminated primarily by renal excretion, up to 96% of an IV dose
Half lifeElimination half life is 2 hours with a prolonged terminal phase of 25 hours.
ClearanceNot Available
ToxicityOverdose may lead to severe hypotension. LD50=1739mg/kg (orally in mice). The most common adverse effects observed in controlled clinical trials were dizziness, cough, chest pain, dyspnea, fatigue, and nausea/vomiting.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Quinapril Metabolism PathwayDrug metabolismSMP00596
Quinapril Action PathwayDrug actionSMP00153
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5597
Blood Brain Barrier-0.9409
Caco-2 permeable-0.8208
P-glycoprotein substrateSubstrate0.8895
P-glycoprotein inhibitor IInhibitor0.7344
P-glycoprotein inhibitor IIInhibitor0.5869
Renal organic cation transporterNon-inhibitor0.8258
CYP450 2C9 substrateNon-substrate0.8594
CYP450 2D6 substrateNon-substrate0.8412
CYP450 3A4 substrateSubstrate0.5356
CYP450 1A2 substrateNon-inhibitor0.8597
CYP450 2C9 inhibitorNon-inhibitor0.6832
CYP450 2D6 inhibitorNon-inhibitor0.8636
CYP450 2C19 inhibitorNon-inhibitor0.6016
CYP450 3A4 inhibitorInhibitor0.5347
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5162
Ames testNon AMES toxic0.9091
CarcinogenicityNon-carcinogens0.9294
BiodegradationNot ready biodegradable0.9596
Rat acute toxicity2.2690 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9763
hERG inhibition (predictor II)Inhibitor0.7176
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pfizer pharmaceuticals ltd
  • Actavis totowa llc
  • Apotex inc
  • Genpharm inc
  • Invagen pharmaceuticals inc
  • Lupin ltd
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc florida
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral40 mg/1
Tablet, film coatedoral5 mg/1
Tabletoral5 mg
Tabletoral10 mg
Tabletoral20 mg
Tabletoral40 mg
Tablet, film coatedoral
Tabletoral10 mg/1
Tabletoral20 mg/1
Tabletoral40 mg/1
Tabletoral5 mg/1
Tabletoral
Prices
Unit descriptionCostUnit
Accupril 10 mg tablet2.02USD tablet
Accupril 20 mg tablet2.02USD tablet
Accupril 40 mg tablet2.02USD tablet
Accupril 5 mg tablet2.02USD tablet
Quinapril 10 mg tablet1.57USD tablet
Quinapril 20 mg tablet1.57USD tablet
Quinapril 40 mg tablet1.57USD tablet
Quinapril 5 mg tablet1.57USD tablet
Quinapril HCl 10 mg tablet1.27USD tablet
Quinapril HCl 20 mg tablet1.27USD tablet
Quinapril HCl 40 mg tablet1.27USD tablet
Quinapril HCl 5 mg tablet1.27USD tablet
Quinaretic 10-12.5 mg tablet1.27USD tablet
Quinaretic 20-12.5 mg tablet1.27USD tablet
Quinaretic 20-25 mg tablet1.27USD tablet
Accupril 10 mg Tablet0.96USD tablet
Accupril 20 mg Tablet0.96USD tablet
Accupril 40 mg Tablet0.96USD tablet
Accupril 5 mg Tablet0.96USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1331615 No1994-08-232011-08-23Canada
CA2023089 No2003-01-142010-08-10Canada
US5684016 No1995-05-042015-05-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point120-130 °CNot Available
water solubility1 mg/LNot Available
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0085 mg/mLALOGPS
logP1.39ALOGPS
logP1.96ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.7ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity119.96 m3·mol-1ChemAxon
Polarizability47.36 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Om P. Goel, Uldis Krolls, “Crystalline quinapril and a process for producing the same.” U.S. Patent US4761479, issued August, 1982.

US4761479
General References
  1. Khan BV, Sola S, Lauten WB, Natarajan R, Hooper WC, Menon RG, Lerakis S, Helmy T: Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care. 2004 Jul;27(7):1712-5. [PubMed:15220251 ]
  2. Kieback AG, Felix SB, Reffelmann T: Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1337-47. doi: 10.1517/17425250903282773. [PubMed:19761414 ]
  3. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, Bass T, Pepine C, Texter M, Haber H, Uprichard A, Cashin-Hemphill L, Lees RS: The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001 May 1;87(9):1058-63. [PubMed:11348602 ]
  4. Tsikouris JP, Suarez JA, Meyerrose GE, Ziska M, Fike D, Smith J: Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? J Clin Pharmacol. 2004 Feb;44(2):150-7. [PubMed:14747423 ]
  5. Valles Prats M, Matas Serra M, Bronsoms Artero J, Mate Benito G, Torguet Escuder P, Mauri Nicolas JM: Quinapril ACE-inhibition effects on adrenergic parameters in moderate essential hypertension. Kidney Int Suppl. 1996 Jun;55:S104-6. [PubMed:8743525 ]
  6. Voors AA, van Geel PP, Oosterga M, Buikema H, van Veldhuisen DJ, van Gilst WH: Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):130-4. [PubMed:15526248 ]
  7. Yamada S, Muraoka I, Kato K, Hiromi Y, Takasu R, Seno H, Kawahara H, Nabeshima T: Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. Biol Pharm Bull. 2003 Jun;26(6):872-5. [PubMed:12808303 ]
External Links
ATC CodesC09AA06C09BA06
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Quinapril.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Quinapril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Quinapril.
AliskirenAliskiren may increase the hyperkalemic activities of Quinapril.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Quinapril.
AmifostineQuinapril may increase the hypotensive activities of Amifostine.
AprotininAprotinin may decrease the antihypertensive activities of Quinapril.
ArdeparinArdeparin may increase the hyperkalemic activities of Quinapril.
AzathioprineQuinapril may increase the myelosuppressive activities of Azathioprine.
BrimonidineBrimonidine may increase the antihypertensive activities of Quinapril.
ButabarbitalButabarbital may increase the hypotensive activities of Quinapril.
ButethalButethal may increase the hypotensive activities of Quinapril.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Quinapril.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Quinapril.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Quinapril.
DemeclocyclineThe serum concentration of Demeclocycline can be decreased when it is combined with Quinapril.
DiazoxideDiazoxide may increase the hypotensive activities of Quinapril.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Quinapril.
DrospirenoneQuinapril may increase the hyperkalemic activities of Drospirenone.
DuloxetineQuinapril may increase the orthostatic hypotensive activities of Duloxetine.
EplerenoneEplerenone may increase the hyperkalemic activities of Quinapril.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Quinapril.
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Quinapril.
HeparinHeparin may increase the hyperkalemic activities of Quinapril.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Quinapril.
HexobarbitalHexobarbital may increase the hypotensive activities of Quinapril.
IcatibantIcatibant may decrease the antihypertensive activities of Quinapril.
InfliximabThe risk or severity of adverse effects can be increased when Quinapril is combined with Infliximab.
IronThe risk or severity of adverse effects can be increased when Quinapril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Quinapril is combined with Iron Dextran.
LanthanumThe serum concentration of Quinapril can be decreased when it is combined with Lanthanum.
LevodopaQuinapril may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Quinapril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Quinapril.
MethohexitalMethohexital may increase the hypotensive activities of Quinapril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Quinapril.
MinocyclineThe serum concentration of Minocycline can be decreased when it is combined with Quinapril.
MolsidomineMolsidomine may increase the hypotensive activities of Quinapril.
MoxifloxacinThe serum concentration of Moxifloxacin can be decreased when it is combined with Quinapril.
MoxonidineMoxonidine may increase the hypotensive activities of Quinapril.
NicorandilNicorandil may increase the hypotensive activities of Quinapril.
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Quinapril.
ObinutuzumabQuinapril may increase the hypotensive activities of Obinutuzumab.
OfloxacinThe serum concentration of Ofloxacin can be decreased when it is combined with Quinapril.
OxytetracyclineThe serum concentration of Oxytetracycline can be decreased when it is combined with Quinapril.
PentobarbitalPentobarbital may increase the hypotensive activities of Quinapril.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Quinapril.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Quinapril.
PregabalinThe risk or severity of adverse effects can be increased when Quinapril is combined with Pregabalin.
PrimidonePrimidone may increase the hypotensive activities of Quinapril.
QuinineQuinine may increase the hypotensive activities of Quinapril.
RisperidoneQuinapril may increase the hypotensive activities of Risperidone.
RituximabQuinapril may increase the hypotensive activities of Rituximab.
SacubitrilThe risk or severity of adverse effects can be increased when Quinapril is combined with Sacubitril.
SecobarbitalSecobarbital may increase the hypotensive activities of Quinapril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Quinapril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Quinapril.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Quinapril is combined with Sodium aurothiomalate.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Quinapril.
TadalafilTadalafil may increase the antihypertensive activities of Quinapril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Quinapril.
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Quinapril.
TizanidineTizanidine may increase the hypotensive activities of Quinapril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Quinapril.
TorasemideTorasemide may increase the hypotensive activities of Quinapril.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Quinapril.
TreprostinilTreprostinil may increase the hypotensive activities of Quinapril.
TriamtereneTriamterene may increase the hyperkalemic activities of Quinapril.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Quinapril.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Quinapril.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Quinapril.
VardenafilVardenafil may increase the antihypertensive activities of Quinapril.
YohimbineYohimbine may decrease the antihypertensive activities of Quinapril.
Food Interactions
  • Do not take with a high-fat meal.
  • Herbs that may attenuate the antihypertensive effect of quinapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of quinapril.
  • Quinapril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Culy CR, Jarvis B: Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs. 2002;62(2):339-85. [PubMed:11817979 ]
  3. Klutchko S, Blankley CJ, Fleming RW, Hinkley JM, Werner AE, Nordin I, Holmes A, Hoefle ML, Cohen DM, Essenburg AD, et al.: Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types. J Med Chem. 1986 Oct;29(10):1953-61. [PubMed:3020249 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23